Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19061465 | FORMULATIONS OF BENDAMUSTINE | February 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 18979375 | Coffee Bean Compositions Comprising Paraxanthine and Methods for Their Production | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18977228 | Ribociclib Tablet | December 2024 | June 2025 | Allow | 7 | 3 | 0 | No | No |
| 18923418 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18829557 | NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18818363 | TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDS | August 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18786785 | METHOD FOR HYPERTHERMIALLY TREATING A CANCER | July 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18758839 | STABLE NIMODIPINE PARENTERAL FORMULATION | June 2024 | March 2025 | Allow | 9 | 1 | 1 | No | No |
| 18739378 | SOLVENT-BASED METHOD FOR MAKING NANOCOMPOSITE PHARMACEUTICAL MATERIAL | June 2024 | August 2024 | Allow | 2 | 0 | 0 | No | No |
| 18737162 | ODOR CONTROL COMPOSITION CONCENTRATES | June 2024 | March 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18646171 | FORMULATIONS OF BENDAMUSTINE | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18646329 | FORMULATIONS OF BENDAMUSTINE | April 2024 | April 2025 | Allow | 12 | 2 | 0 | No | No |
| 18643086 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | April 2024 | May 2025 | Allow | 13 | 2 | 0 | No | No |
| 18641845 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18641848 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18632164 | PAINLESS NGF FOR FRACTURE REPAIR | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18629406 | METHOD AND KIT FOR BOWEL PREPARATION | April 2024 | April 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18624804 | Personal Care Formulations | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18616858 | Cannabinoid Pouch | March 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18616577 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18616603 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18612888 | CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | March 2024 | May 2025 | Allow | 14 | 0 | 0 | Yes | No |
| 18603884 | TAMPER RESISTANT DOSAGE FORMS | March 2024 | July 2024 | Allow | 4 | 3 | 0 | No | No |
| 18602981 | PHARMACEUTICAL CAPSULES COMPRISING LUMATEPERONE MONO-TOSYLATE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18599893 | HIGH STEROL-CONTAINING LIPID NANOPARTICLES | March 2024 | April 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18599125 | METHOD OF TREATING DISEASES | March 2024 | January 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 18599127 | METHOD OF TREATING DISEASES | March 2024 | January 2025 | Allow | 10 | 2 | 0 | No | No |
| 18598402 | Devices for Treating Diseases and Conditions | March 2024 | May 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18594725 | MODULATORS OF TNF-ALPHA ACTIVITY | March 2024 | February 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18587736 | EMBOLIC COMPOSITIONS | February 2024 | April 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18582320 | PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATE | February 2024 | June 2025 | Allow | 16 | 1 | 1 | No | No |
| 18444175 | ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18443353 | PERSONAL CARE COMPOSITION COMPRISING WATER INSOLUBLE SOLID ORGANIC COMPOUND | February 2024 | September 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18441930 | ALLERGEN DESENSITIZATION METHOD | February 2024 | May 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18437368 | CAPSULE FORMULATIONS | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18436814 | Method for Synthesizing Selenium Nanoparticles from Edible Mushrooms | February 2024 | April 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18436404 | Method for Synthesizing Selenium Nanoparticles from Edible Mushrooms | February 2024 | March 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18435678 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | February 2024 | March 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18681556 | PREPARATION OF COMPOSITE GELS, POLYMER SCAFFOLDS, AGGREGATES AND FILMS COMPRISING SOLUBLE CROSS-LINKED CHITOSAN & USES THEREOF | February 2024 | May 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18431035 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18429916 | METHODS OF PEST CONTROL IN SOYBEAN | February 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18427459 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18426704 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18426211 | 9-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18426092 | 9-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18421535 | 2-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 1 | 1 | No | No |
| 18412318 | COMPOSITIONS AND METHODS FOR THEIR PRODUCTION | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18408463 | METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANT | January 2024 | January 2025 | Allow | 13 | 2 | 0 | No | No |
| 18405512 | COMPOSITION USED FOR THERAPEUTIC TREATMENT OF SKIN DISEASE | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18575483 | CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS | December 2023 | February 2025 | Allow | 14 | 1 | 1 | No | No |
| 18397626 | PROCESS OF MAKING NANOEMULSION | December 2023 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18396828 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION | December 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18395521 | IMPLANTABLE POLYMER FOR BONE AND VASCULAR LESIONS | December 2023 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18392543 | HYDROGEL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF PEDIATRIC GROWTH PLATE INJURIES | December 2023 | May 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18572144 | FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES | December 2023 | April 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18542954 | PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY | December 2023 | February 2025 | Allow | 14 | 1 | 1 | No | No |
| 18538502 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18535261 | WATER-IN-SILICONE COMPLEXION EMULSIONS | December 2023 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18535520 | DEGRADANT COMPOUND IN A MEDICAMENT | December 2023 | December 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18532596 | MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIB | December 2023 | August 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18531424 | HETEROCYCLIC COMPOUNDS AND THEIR USES | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18531082 | FORMULATIONS COMPRISING CARBACHOL AND BRIMONIDINE TO ENHANCE ANTI-PRESBYOPIA EFFECTS | December 2023 | February 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18529962 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS | December 2023 | August 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18522062 | ORAL PATCH FOR TREATING MOUTH ULCERS | November 2023 | August 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18519530 | POLYMER PARTICLES FOR NEUTROPHIL INJURY | November 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18514306 | MODIFIED WOUND DRESSINGS | November 2023 | November 2024 | Allow | 12 | 1 | 0 | No | No |
| 18512499 | CANCER TREATMENT METHOD FOR MAGNETIC HYPOTHERMIA CANCER TREATMENT | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18512722 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | November 2023 | July 2024 | Allow | 8 | 2 | 0 | No | No |
| 18511751 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | November 2023 | November 2024 | Abandon | 12 | 0 | 0 | No | No |
| 18508748 | IMAC-ENRICHED MICROALGAL CULTURE SUPERNATANT AND USES THEREOF | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18504345 | PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATE | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18387755 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | November 2023 | April 2024 | Allow | 5 | 1 | 1 | No | No |
| 18502684 | 2-BENZO-[3,4-B]QUINOLINO-[B,G]INDENO[1',2':3,4]FLUORENO-[1,2-D]OXONINE-24-CHLORO-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18387202 | 9-(6-FLOURO-2-HYDROXYOUINOLIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18502663 | ORAL CANNABINOID PRODUCT WITH LIPID COMPONENT | November 2023 | April 2025 | Allow | 17 | 1 | 1 | No | No |
| 18386560 | 2-BENZO-[3,4-B] QUINOLINO-{B,G]INDENO [1',2':3,4] FLUORENO-[1,2-D] OXONINE-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18386579 | 3-(4-BROMOPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | August 2024 | Allow | 9 | 2 | 1 | No | No |
| 18500416 | OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18499240 | ASTAXANTHIN PICKERING EMULSION WITH COLON TARGETED DELIVERY FUNCTION, AND PREPARATION METHOD AND APPLICATION METHOD THEREOF | November 2023 | October 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18385589 | 10-(2-HYDROXYETHYL)-9-(2-HYDROXYPYRIDIN-3-YL)-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18493990 | COSMETIC COMPOSITIONS, KITS THEREOF, AND METHODS FOR MAKING AND USING THE SAME | October 2023 | June 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18494341 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | October 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18491443 | CLAY NANOPARTICLES FOR MEDICAL USE | October 2023 | March 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18488231 | CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLD | October 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18487995 | 2-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | November 2024 | Abandon | 13 | 3 | 1 | No | No |
| 18379964 | 6'-(3-CHLOROPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18379966 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18485929 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18378009 | Synthesis and Antimicrobial Uses of Dinuclear Silver(I) Pyrazolates | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18480331 | MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY | October 2023 | October 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18477642 | SOLID COSMETIC COMPOSITION COMPRISING A SILICONE POLYAMIDE, A SILICONE RESIN AND A DISPERSED AQUEOUS PHASE | September 2023 | February 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18478482 | METHODS OF TREATMENT COMPRISING ADMINISTERING LUMATEPERONE MONO-TOSYLATE CAPSULES | September 2023 | June 2025 | Allow | 21 | 2 | 0 | No | No |
| 18373603 | Medical Implants And Methods Of Manufacture | September 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18475755 | TAMPER RESISTANT DOSAGE FORMS | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18474782 | Perfume Compositions | September 2023 | December 2024 | Allow | 14 | 1 | 1 | No | No |
| 18474798 | Perfume Compositions | September 2023 | March 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18552411 | BIOFLEXIBLE ELASTOMER INTESTINAL ANASTOMOSIS STENT BASED ON PTMC-B-PEG-B-PTMC COPOLYMER, AND PREPARATION METHOD | September 2023 | May 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18372560 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | September 2023 | December 2024 | Allow | 15 | 2 | 0 | No | No |
| 18372162 | Therapeutic Composition and Methods | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18371084 | Method for Synthesizing Selenium Nanoparticles from Edible Mushrooms | September 2023 | May 2025 | Abandon | 20 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1613.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1613 is part of Group 1610 in Technology Center 1600. This art unit has examined 10,148 patent applications in our dataset, with an overall allowance rate of 49.9%. Applications typically reach final disposition in approximately 30 months.
Art Unit 1613's allowance rate of 49.9% places it in the 7% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1613 receive an average of 2.34 office actions before reaching final disposition (in the 84% percentile). The median prosecution time is 30 months (in the 40% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.